AAV Vector Antisense Oligonucleotide Exon 53 Skipping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for Duchenne muscular dystrophy (DMD) face challenges in stably introducing antisense oligonucleotides into muscle fibers, with existing methods requiring frequent injections and potential toxicity at high doses, and the complexity of choosing effective antisense sequences for exon skipping.
Innovation Solution
A recombinant adeno-associated viral vector (AAVr) carrying a judiciously chosen antisense oligonucleotide (AON) targeting exon 53 of the dystrophin gene, combined with a modified snRNA, to efficiently skip exon 53 and produce a truncated but functional dystrophin protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If naked antisense oligonucleotides are directly injected, then the treatment can be administered, but frequent injections are required due to short lifespan in muscle
Solution Approach 1:
The patent uses chemical modifications (2'-O-methyl, phosphorothioate backbone) as intermediary structures that protect the antisense oligonucleotide from degradation by nucleases in the muscle tissue, thereby extending its lifespan and reducing injection frequency
Solution Approach 2:
The patent employs chemically modified oligonucleotides that are more stable and longer-lasting in the muscle tissue, replacing the need for frequent administrations of naked oligonucleotides
2Stability of the object's composition
If chemically modified oligonucleotides are used at high doses, then stability in vivo is improved, but toxicity increases
Solution Approach 1:
The patent optimizes the chemical structure parameters of the oligonucleotide (2'-O-methyl modifications, phosphorothioate backbone) to achieve the right balance between stability and reduced toxicity, allowing effective doses with improved safety profile
3Duration of action of stationary object
If recombinant adeno-associated viral vectors are used, then long-term expression is achieved, but the complexity of vector design and production increases
Solution Approach 1:
The patent uses recombinant adeno-associated viral vectors that are pre-designed to carry the antisense oligonucleotide sequence, enabling long-term stable expression of dystrophin exon 53 skip variants with a single administration
Solution Approach 2:
The AAV vector serves as an intermediary delivery system that protects the oligonucleotide sequence and facilitates its long-term expression in muscle tissue, overcoming the limitations of direct injection
4Reliability
If exon skipping strategy is applied, then reading frame is restored, but the complexity of selecting effective antisense sequences increases
Solution Approach 1:
The patent targets specific local regions within exon 53 (such as the 5' or 3' portions) with designed antisense oligonucleotides, achieving effective reading frame restoration while simplifying the selection process by focusing on critical splicing regulatory regions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves long-term expression of a truncated dystrophin protein, providing a promising therapeutic tool for DMD by optimizing the delivery and stability of AONs, reducing the need for frequent injections and minimizing toxicity.
Implementation Method 1
l'oligonucléotide antisens est dirigé contre un segment d'au moins 33 bases de la région +30 à +69 de l'exon 53 de l'ARN pré-messager de la dystrophine
Data Source
Figure 1~2
Figure 3
Figure 4A~4B
AI summary
The invention relates to a recombinant adeno-associated viral vector (rAAV) comprising a sequence encoding an antisense oligonucleotide (AON) directed against a segment of at least 33 bases from the +30 to +69 region of exon 53 of the pre-messenger RNA (pre-mRNA) of dystrophin, advantageously of human origin, and to the use thereof as a drug, in particular for the treatment of Duchenne muscular dystrophy (DMD).